Duchenne Biotechnology Council

In 2016, Jett Foundation launched a collaborative program called the Duchenne Biotechnology Council (DBC). As a non-profit organization in the Duchenne space, Jett Foundation wants all safe and effective potential treatments or cures for Duchenne to get to patients as fast as possible. Our organization believes that the most effective way to do achieve this goal is collaboration among all stakeholders, including among pharmaceutical companies in are interested in Duchenne. 

The DBC is a group of industry partners in the Duchenne space who have come together to try to solve some of the major barriers to innovation that they all face in Duchenne drug development. As a team, these pharmaceutical companies, with different technologies, intellectual properties, and cultures, have committed to meeting quarterly to brainstorm and then tackle the common challenges they all face as drug developers in Duchenne.

For information on member companies or on becoming a member of the DBC, please contact Jordan McSherry at jordan@jettfoundation.org. 

*2018 Duchenne Biotechnology Council Meetings

Tuesday, February 28, 2018, 3pm-5pm at the Royal Sonesta Boston

Wednesday, May 3rd, 2018, 8am-10am, Location TBA

*Additional 2018 meeting dates TBA